By Kerrin Green, MA Assistant Managing Editor
From time to time, the National Comprehensive Cancer Network® (NCCN®) convenes experts from within and beyond NCCN Member Institutions to expand on issues assessed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) and to discuss issues outside the scope of the NCCN Guidelines™.
Two new NCCN Task Force Supplements are now available free of charge, offering one hour of CME credit for successful completion (tests can be submitted online):
NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma with Molecular Targeted Therapy
The biggest challenges for physicians treating renal cell carcinoma are in selecting the optimal treatment for a given patient from a growing list of agents, and how to effectively manage toxicities. This report summarizes the background data presented at the task force meeting addressing the clinical issues associated with molecular targeted therapies in an attempt to help practicing oncologists optimize patient outcomes. Click here to view the full report.
NCCN Task Force Report : Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients with Chronic Myelogenous Leukemia
The goal of therapy for patients with chronic myelogenous leukemia (CML) is the achievement of a complete cytogenetic response, and eventually a major molecular response, to prevent disease progression to accelerated or blast phase. Selecting the appropriate tyrosine kinase inhibitor (TKI) depends on many factors. This report provides recommendations regarding the selection of TKI therapy for the management of patients with CML based on the evaluation of available published clinical data and expert opinion among the task force members. Click here to view the full report.
For the complete versions of these and other NCCN supplements, please visit JNCCN.org.